The anthelmintic drug praziquantel (PZQ) is used to treat schistosomiasis, a neglected tropical disease that affects over 200 million people. The target of PZQ in the blood fluke responsible for this disease is unknown. Here, we demonstrate that PZQ activates a transient receptor potential (TRP) channel found in parasitic schistosomes and other PZQ-sensitive parasites.
Schistosomiasis (Bilharzia) is a parasitic worm infection that infects millions of people worldwide [1, 2] . Mature parasites living in the vasculature lay eggs which become deposited in host tissues where they trigger local inflammatory responses. Chronic infections become associated with fibrosis and obstructive disease in gastrointestinal tissues and liver (S. mansoni, S. japonicum), genitourinary disease (S. haematobium), anemia, undernutrition and a heightened risk for many comorbidities. No effective vaccine currently exists for schistosomiasis [3] . The resulting annual disease burden, especially impactful for school-age children, has been estimated a loss of 70 million disability-adjusted life years [1, 2] .
In 2017, approximately 100 million people (around 80 million school-aged children) received free preventive treatment for schistosomiasis. The drug praziquantel (PZQ), discovered ~40 years ago, is the key treatment. PZQ is also used to treat other parasitic infections, caused by tapeworms and trematodes. The clinical formulation of PZQ is a racemate (±PZQ) composed of the enantiomers (R)-PZQ and (S)-PZQ. (R)-PZQ is the anti-schistosomal eutomer, which causes Ca 2+ influx and spastic paralysis of adult worms, with (S)-PZQ regarded as a less active distomer [4, 5] . From a treatment perspective, it is problematic that despite decades of clinical use, as well as demonstration of PZQ resistance in both lab and field, the target of PZQ remains unknown [6] . Resolution of the target of PZQ action in the parasite would be enabling for discovering new anthelmintics and vulnerabilities within signaling pathways engaged by PZQ.
This lack of knowledge has proved a longstanding roadblock in this field.
Here, we demonstrate (R)-PZQ activates a Ca 2+ permeable schistosome transient receptor potential (TRP) channel, broadly expressed in PZQ-sensitive flatworms.
Results
Addition of (R)-PZQ (100nM) to adult schistosome worms in vitro caused a rapid, spastic paralysis ( Figure 1A ). Addition of the same concentration of (S)-PZQ was ineffective at causing muscle contraction ( Figure 1A ). These effects reflect the different potency of these enantiomers against schistosomes (EC 50 for (R)-PZQ = 68±7nM, EC 50 for (S)-PZQ= 1.1±0.4µM, ~16-fold difference, Figure 1B ) in vitro and in vivo [4] .
While no binding site(s) for these enantiomers have been identified in the parasite, there has been considerable recent progress in identifying targets for (R)-PZQ and (S)-PZQ in the human host [7] . (R)-PZQ acts as a partial agonist of the human 5-hydroxytryptamine 2B receptor (5HT 2B R, [8] ) and (S)-PZQ is a partial agonist of the human transient receptor potential melastatin-8 channel (hTRPM8, [9] ). While regulation of these host targets occurs over a micromolar concentration range (EC 50 for ±PZQ at 5-HT 2B R ~8µM [8] , EC 50 for ±PZQ at hTRPM8 ~20-25µM [9, 10] ), molecular divergence between human and flatworm ligand binding pockets [11, 12] makes it reasonable to anticipate different affinities at homologous schistosome target(s). Full concentration-response curves were performed with (R)-PZQ ( Figure 2C ), (S)-PZQ and ±PZQ ( Figure 2D ). Sm.TRPM PZQ was activated by ±PZQ with an EC 50 of 1.08±0.14µM ( Figure   2D ) and this activation was stereoselective, with the (R)-PZQ evoking Ca 2+ signals over a considerably lower concentration range (EC 50 of 597±10nM) than (S)-PZQ (EC 50 of 27.9±3.1µM, Figure 2D ). This concentration range, and the clear difference between (R)-PZQ and (S)-PZQ sensitivity (~50-fold), is consistent with the action of PZQ on schistosome muscle (Figure 1 ).
Finally, when the incubation temperature was increased to 37°C, (R)-PZQ activated Sm.TRPM PZQ over a lower concentration range (EC 50 =154±33nM, Figure 2E ).
Consistent with our homology search approach, Sm.TRPM PZQ displays sequence homology with the hTRPM subfamily ( Figure 2F ). Sequence analysis revealed an architecture characteristic of TRPM channels ( Figure 2G ), a family which is well represented within flatworm genomes [13] .
Features include a long NH 2 -terminal TRPM homology region (MHR) domain, followed by six predicted transmembrane (TM) domains with a pore-forming re-entry loop between TM5 and TM6, a conserved TRP helix juxtaposed to a coiled-coil region, and a cytoplasmic COOH terminal enzymatic domain ( Figure 2F ). This enzyme domain shows homology with the human ADP ribose (ADPR) pyrophosphatase NUDT9, a feature characteristic of TRMP2 channels [14] [15] [16] [17] . Analysis of Sm.TRPM PZQ in transcriptomic datasets evidences expression across various parasite life cycle stages [18] , and analysis of flatworm genomes revealed expression of closely related TRPM channels in both free-living and parasitic flatworms that exhibit sensitivity to PZQ ( Supplementary Figure 3 ).
In conclusion, these experiments have identified a Ca 2+ -permeable schistosome TRPM channel activated by (R)-PZQ in the nanomolar range.
Discussion
These data identify a schistosome TRP channel (Sm.TRPM PZQ ) activated by ±PZQ, a discovery that represents the first report of a flatworm target activated by this drug. Identification of a TRPM2-like channel as a ±PZQ target is appealing as it consistent with several known facets of PZQ action.
First, ±PZQ has long been known to cause a sustained Ca 2+ influx and acute paralysis of schistosome worms [5] . Sm.TRPM PZQ is a Ca 2+ permeable channel that supports long lasting cellular Ca 2+ signals resulting from Ca 2+ entry (Figure 2 ). hTRPM2 is known to exhibit long channel opening times that support substantial Ca 2+ influx [17, 19] . Second, exposure to ±PZQ causes muscle and tegumental damage in schistosomes [5] . hTRMP2 is a well-known effector of apoptosis being responsive to reactive oxygen species on account of activation by H 2 O 2 and adenosine 5'-diphosphoribose (ADPR, [17, 20] ). Activation of hTRMP2, at the cell surface and within intracellular organelles, causes lysosomal permeabilization and cell death [20] [21] [22] . Such actions potentially explain the deleterious effects of ±PZQ on the worm surface. Third, hTRMP2 has a physiological role as a thermosensitive channel sensing non-noxious warmth (reviewed in [19, 23] ). Temperature changes are known to depolarize schistosome tegument and muscle [24] . Given the varied environmental transitions experienced during the parasitic life cycle perhaps Sm.TRPM PZQ fulfills a critical role in parasite physiology as a thermosensor, which is dysregulated by PZQ. Future work will investigate the mechanisms of endogenous Sm.TRPM PZQ channel activation, and synergism between channel ligands and environment.
Finally, consistent with Sm.TRPM PZQ being a target of this clinically important therapeutic, Sm.TRPM PZQ is expressed through various parasite life cycle stages [18] and is present in other flatworms sensitive to PZQ ( Supplementary Figure 3) .
Identification of Sm.TRPM PZQ as a ±PZQ target is significant as this discovery enables execution of target-based screens to discover new scaffolds active at Sm.TRPM PZQ that may yield novel anthelmintics. It also provides a molecular handle on key questions for chemotherapy, such as how is Sm.TRPM PZQ differentially regulated in juvenile worms which have less sensitivity to PZQ, likely a contributory factor driving drug resistance. A key point is that (R)-PZQ acts as a potent activator of Sm.TRPM PZQ in the nanomolar range ( Figure 2 ). Existing regulators of hTRPM2 act over the micromolar range -for example, hTRPM2 activates in response to micromolar levels of the endogenous agonist ADPR [17] . This is important as hTRPM2 is an emerging clinical target for several nervous system and inflammatory disorders [17, 19] .
Although hTRPM2 does not appear to be activated by PZQ [9] , understanding the basis of (R)-PZQ affinity for Sm.TRPM PZQ and comparing regulation and gating of Sm.TRPM PZQ with recently solved TRPM2 structures from vertebrates [14, 15] and other invertebrates [16] may help catalyze drug design at this clinically important target.
Finally, this discovery will prioritize subsequent analyses of other schistosome TRPM channels and splice variants both to assess broader PZQ sensitivity in this clade, and to understand their roles in parasite (patho)physiology which remain largely unexplored.
Methods
Reagents. Enantiomers of ±PZQ were resolved following the protocol published by Woelfle et al. [25] . All chemical reagents were sourced from Sigma. Cell culture reagents were from Invitrogen. Lipofectamine 2000 was from ThermoFisher. (Greiner Bio-one, Germany). After loading, the Ca 2+ assay was performed at room temperature.
Basal fluorescence was monitored for 20s, then 25μl of each drug was added, and the signal (raw fluorescence units) was monitored over an additional 250s. For quantitative analyses, peak fluorescence in each well was normalized to maximum-fold increase over baseline. Changes in fluorescence amplitude were analyzed using the sigmoidal dose-response function in Origin. containing an ankyrin-like repeat domain (brown, [16] ), the pre S1 helix (shaded), the six transmembrane (TM) spanning helices (S1-S6, blue) with the pore helix between S5 and S6 (red), the TRP domain (purple), the rib and pole helices (yellow), an additional helical domain (CC, black) and the COOH terminal NUDT9H domain. 
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